Detalhe da pesquisa
1.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Lancet Oncol
; 25(2): 184-197, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211606
2.
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Breast Cancer Res Treat
; 196(1): 97-109, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36040640
3.
The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.
Int J Cancer
; 141(1): 129-142, 2017 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28294317
4.
Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified.
World J Surg Oncol
; 11: 91, 2013 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23607710
5.
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Cell Res
; 33(5): 389-402, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36973538
6.
RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer.
Breast Cancer Res Treat
; 133(1): 111-6, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21811815
7.
Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.
Ann Surg Oncol
; 19(9): 3019-27, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22451233
8.
Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population.
World J Surg Oncol
; 10: 152, 2012 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22805492
9.
Breast-conserving in centrally located breast cancer patients confirmed safe by SEER based study.
Gland Surg
; 11(1): 226-235, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35242684
10.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Clin Cancer Res
; 28(13): 2807-2817, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247906
11.
A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
Ann Transl Med
; 9(4): 301, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33708928
12.
Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery.
Front Oncol
; 11: 690658, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34527574
13.
Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population.
Breast Cancer Res Treat
; 123(1): 133-8, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19921424
14.
Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population.
Breast Cancer Res Treat
; 119(2): 295-303, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19238535
15.
Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer.
Front Oncol
; 10: 27, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32117708
16.
Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk.
Ann Transl Med
; 8(21): 1417, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33313162
17.
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Nat Commun
; 11(1): 5679, 2020 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33173047
18.
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Breast Cancer Res Treat
; 115(1): 51-5, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18483852
19.
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Breast Cancer Res Treat
; 114(3): 457-62, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18446436
20.
Insights Into Breast Cancer in the East vs the West: A Review.
JAMA Oncol
; 5(10): 1489-1496, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31095268